Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1990-4-19
pubmed:abstractText
Alterations in proteoglycans (PG) located in the pulmonary interstitium may influence extracellular matrix (ECM) structure and assembly during the development of diseases in which increased numbers of neutrophils enter the lung. To evaluate potential mechanisms of PG degradation, neutrophils or purified neutrophil products were incubated with ECM that had been produced by cultured neonatal rat vascular smooth muscle cells (SMC) or lung fibroblasts (LF) and metabolically labeled with 35SO4. Matrix PG solubilization was expressed as a percentage of the spontaneous [35SO4]PG solubilization that occurred in the presence of buffer alone. Solubilization by unstimulated neutrophils was 105.8 +/- 3.1% (mean +/- SEM, n = 6) and 101.7 +/- 3.05 (n = 8) using ECM that had been produced by LF and SMC, respectively. Solubilization by neutrophils that had been stimulated with formyl-methionine-leucine-phenylalanine (FMLP) in the presence of cytochalasin B (CB) was 189.7 +/- 5.8% and 298.2 +/- 26.2% using ECM produced by LF and SMC, respectively. Matrix that had been produced by SMC was used to evaluate which neutrophil products were responsible for the degradation of PG. Addition of a specific inhibitor of neutrophil elastase (NE) to stimulated polymorphonuclear leukocytes (PMN) reduced PG solubilization by 88.3 +/- 4.8% (n = 8). Addition of an inhibitor of cathepsin G (CG), as well, did not further reduce PG degradation. Purified CG and myeloperoxidase solubilized significantly more PG, 125.8 +/- 6.2% (n = 9) and 143.2 +/- 8.1% (n = 6), respectively (P less than 0.01), than was solubilized spontaneously.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1044-1549
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
271-9
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:2155632-Animals, pubmed-meshheading:2155632-Cathepsin G, pubmed-meshheading:2155632-Cathepsins, pubmed-meshheading:2155632-Cells, Cultured, pubmed-meshheading:2155632-Chromatography, Gel, pubmed-meshheading:2155632-Extracellular Matrix, pubmed-meshheading:2155632-Fibroblasts, pubmed-meshheading:2155632-Glycosaminoglycans, pubmed-meshheading:2155632-Humans, pubmed-meshheading:2155632-Lung, pubmed-meshheading:2155632-Muscle, Smooth, Vascular, pubmed-meshheading:2155632-Neutrophils, pubmed-meshheading:2155632-Pancreatic Elastase, pubmed-meshheading:2155632-Peroxidase, pubmed-meshheading:2155632-Proteoglycans, pubmed-meshheading:2155632-Rats, pubmed-meshheading:2155632-Rats, Inbred Strains, pubmed-meshheading:2155632-Serine Endopeptidases, pubmed-meshheading:2155632-Solubility
pubmed:year
1990
pubmed:articleTitle
Mechanisms of extracellular matrix proteoglycan degradation by human neutrophils.
pubmed:affiliation
Department of Veterans Affairs Research Service, IA.
pubmed:publicationType
Journal Article